Baseline patient characteristics can predict which patients are at a higher risk of presentation with bleeding after antithrombotic treatment. Several studies have identified predictors of major bleeding. It has been suggested that Asians may respond differently to anti-thrombotic therapy with increased vulnerability to the use of antiplatelet and anticoagulant agents. 3 Instead of the usual daily dose of prasugrel 10 mg, it has been reported that for East Asians following ACS, prasugrel 5 mg/d may be the optimal antiplatelet dose. 4 On the other hand, a retrospective analysis from the Platelet Inhibition and Patient Outcomes trial, which found that ticagrelor was superior to clopidogrel for decreasing CV events in ACS with a cost of increased nonfatal hemorrhage, showed consistent results for non-Asians and a small group of Asians with also no increase in hemorrhage in the Asians. 5 Specific contemporary management and outcomes of an ACS with a non-STEMI in Asian patients have not been well characterized. 6, 7 Current treatment of ACS has evolved to include rapid revascularization, potent antithrombotics, and antiplatelet agents, all of which reduce the risk of ischemic complications. New drugs have been developed with the aim of a more predictable pharmacological profile, a lower bleeding risk, and lower rates of interpatient variability. 8 However, despite therapeutic advances, hemorrhage still represents the major noncardiac complication following treatment of these patients. Several studies have examined predictors of major bleeding (age, sex, baseline renal function, anemia, and ethnicity) or developed predictive instruments for the estimation of bleeding risk in this population. 9, 10 In the article by Misumida et al entitled "Higher Risk of Bleeding in Asians Presenting with ST-elevation Myocardial Infarction: Analysis of the National Inpatient Sample Database," the authors described that Asian patients with STEMI had a higher incidence of inhospital major bleeding than Caucasian patients and that Asian ethnicity was an independent predictor for major bleeding complications in the entire study cohort and in all subgroups treated with medical therapy, percutaneous coronary intervention (PCI), and coronary artery bypass graft surgery. 11 The data were obtained from The Nationwide Inpatient Sample database from 2002 to 2013, which identified all hospitalized patients older than 18 years with a primary diagnosis of STEMI. A total of 1 742 243 patients were included in the final analysis with 1 695 680 Caucasian patients and 46 563 Asian patients. 11 The incidence of major bleeding and inhospital deaths were 2.3% and 8.7%, respectively. Asian patients had a higher incidence of major bleeding (3.6% vs 2.2%, P < .001), intracranial hemorrhage (0.4% vs 0.2%, P ¼ .02), and administration of blood transfusions for a bleeding event (3.3% vs 2.0%, P < .001).
There are several potential explanations for the observed increased risk of bleeding in Asian patients. Recent reports have suggested that Asians may respond differently to antithrombotic medications. In a study of Chinese patients with acute myocardial infarction, patients were administered a 50% lower dose compared with standard Western regimens of recombinant tissue plasminogen activator but showed similar infarctrelated artery patency rates. 12 The Clopidogrel and Metoprolol in Myocardial Infarction/Second Chinese Cardiac Study (COMMIT/CCS-2) trial showed a significant mortality benefit with clopidogrel treatment in the Chinese patients presenting with acute myocardial infarction without using a loading dose. 13 Studies with warfarin demonstrated lower 1 Gill Heart and Vascular Institute, University of Kentucky, Lexington, KY, USA dosage requirements in Asians compared with Hispanics, Caucasians, and African Americans. 14 East Asians have been shown to have an increased risk of intracranial hemorrhage with warfarin compared with Westerners so that a lower target for the international normalized ratio (1.6-2.6) has been proposed. 15 Genetic variation of gene polymorphism appears to be the explanation with much to be learned. Some polymorphisms of cytochrome P450 2C9 appear to be hyperresponders to warfarin as shown in a group of Chinese patients, resulting in an indication for a lower dose of warfarin. 16 On the other hand, in the same study, Chinese patients with some polymorphisms of vitamin K epoxide reductase complex 1 (VKORC1) had a reduced response to warfarin so that increased warfarin dosage was indicated. 16 A similar result with Japanese pediatric patients was observed with some VKORC1 polymorphisms with an indication for decreased warfarin dosage. 17 Methylenetetrahydrofolate reductase C677T polymorphism has had some association with an increased risk of intracerebral hemorrhage in Chinese populations. 18 An increased incidence of patients with low platelet reactivity has been reported among Koreans. 19 Another important factor is to review baseline physiologic characteristics exhibited by the study population. Some Asian groups have increased rates of relative anemia and slight rates of increased renal impairment. 20, 21 Also, there is an increased risk of renal insufficiency in some Asian groups following cardiac surgery. 22 These factors have previously been shown to increase vulnerability to excess antithrombotic overdosing. 23 Physician practices such as using estimated instead of directly measured weights or using serum creatinine instead of creatinine clearance, which underestimates renal insufficiency particularly in the setting of low body mass index, contribute to dosing inaccuracies. 24 It is of interest that administration of a statin has been reported to show benefit in decreasing the incidence of contrast-induced renal injury in patients including an East Asian population. 25 This is another analogy of dosing differences with respect to ethnicity and is a further link to effecting a decrease in the risk of hemorrhage in Asians following ACS and PCI.
The study of Misumida et al supports the observation that appropriate dosing of medications may require additional adjustment based on ethnicity.
11 Several factors involving the Asian population explain their requirement of lower dosing of antithrombotic therapies compared with other racial groups. Much additional investigative work needs to be performed. Obviously, "one size does not fit all" and the key point is that the clinician must be aware of the increased risk of hemorrhage in Asians, assess each patient's response individually, and then treat with anticoagulants and platelet inhibitors accordingly to achieve an adequate effect while avoiding increased risk of hemorrhage. Perhaps in the future, there will be available rapid genetic analyses to offer specific guidance, but this is not currently the case. Therefore, awareness of increased bleeding risk in Asians as a group, leading to extra care with anticoagulants and platelet inhibitors, is in order to avoid complications and achieve optimum therapeutic results in CV and other patients.
